<DOC>
	<DOCNO>NCT00074139</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , doxorubicin , cyclophosphamide , use different way stop tumor cell divide stop grow die . Combining one drug give different time , may kill tumor cell . It yet know combination chemotherapy regimen effective breast cancer . PURPOSE : Randomized phase I trial compare effectiveness two regimen docetaxel combine doxorubicin cyclophosphamide treat woman advance breast cancer .</brief_summary>
	<brief_title>Docetaxel , Doxorubicin , Cyclophosphamide Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacokinetic profile docetaxel , doxorubicin , cyclophosphamide woman advance breast cancer . Secondary - Compare pharmacokinetic profile regimen patient vs historical pharmacokinetic profile docetaxel . OUTLINE : This randomize , open-label , crossover , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin IV 15 minute cyclophosphamide IV 15 minute day 1 follow doxorubicin IV 15 minute , cyclophosphamide IV 15 minute , docetaxel IV 1 hour day 22 . - Arm II : Patients receive doxorubicin IV 15 minute , cyclophosphamide IV 15 minute , docetaxel IV 1 hour day 1 follow doxorubicin IV 15 minute cyclophosphamide IV 15 minute day 22 . Treatment arm continue absence disease progression unacceptable toxicity . Patients may receive additional therapy discretion treat physician . Patients follow 3-4 week . PROJECTED ACCRUAL : A total 24 patient ( 12 per treatment arm ) accrue study within 7 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced breast cancer Adjuvant set highrisk disease allow No symptomatic evidence history brain metastases No leptomeningeal metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 69 Sex Female Menopausal status Not specify Performance status WHO 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic Bilirubin less upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 1.5 time ULN alkaline phosphatase great 2.5 time ULN ) Alkaline phosphatase great 5 time ULN Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular LVEF shorten fraction great low limit normal MUGA echocardiography Cardiac function normal No congestive heart failure No unstable angina pectoris No myocardial infarction within past year No uncontrolled hypertension No highrisk uncontrolled arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No active uncontrolled infection No active peptic ulcer No unstable diabetes mellitus No serious illness medical condition No contraindication corticosteroids No preexist grade 2 great motor sensory neurotoxicity No psychological , social , familial , geographical reason would preclude study followup No history significant neurologic psychiatric disorder ( e.g. , psychotic disorder , dementia , seizure ) would preclude understand give informed consent No neoplasm within past 10 year except curatively treat nonmelanoma skin cancer , carcinoma situ cervix , ipsilateral ductal carcinoma situ breast , lobular carcinoma situ breast PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 6 month since prior anthracycline taxoid ( e.g. , paclitaxel docetaxel ) therapy No prior cumulative anthracycline dose great 240 mg/m^2 Endocrine therapy Concurrent corticosteroid treatment allow provide treatment initiated 6 month study entry dose less 20 mg methylprednisolone equivalent No concurrent ovarian hormonal replacement therapy Radiotherapy Not specify Surgery More 2 week since prior major surgery Other More 30 day since prior participation another clinical trial investigational drug device No concurrent experimental drug No concurrent systemic anticancer therapy No concurrent aminoglycoside antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>